Epclusa is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences, Inc.. The primary component is Sofosbuvir; Velpatasvir.
Product ID | 61958-2203_40f3a9f4-caa0-4d29-8080-1815053c6553 |
NDC | 61958-2203 |
Product Type | Human Prescription Drug |
Proprietary Name | Epclusa |
Generic Name | Velpatasvir And Sofosbuvir |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2020-03-19 |
Marketing Category | NDA / NDA |
Application Number | NDA208341 |
Labeler Name | Gilead Sciences, Inc. |
Substance Name | SOFOSBUVIR; VELPATASVIR |
Active Ingredient Strength | 200 mg/1; mg/1 |
Pharm Classes | Breast Cancer Resistance Protein Inhibitors [MoA], Hepatitis C Virus NS5A Inhibitor [EPC], Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], RNA Replicase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2020-03-19 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208341 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2020-03-18 |
Ingredient | Strength |
---|---|
VELPATASVIR | 50 mg/1 |
SPL SET ID: | 7f30631a-ee3b-4cfe-866b-964df3f0a44f |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
61958-2201 | Epclusa | Velpatasvir and Sofosbuvir |
61958-2203 | Epclusa | Velpatasvir and Sofosbuvir |
61958-2204 | Epclusa | Velpatasvir and Sofosbuvir |
61958-2205 | Epclusa | Velpatasvir and Sofosbuvir |
72626-2701 | Sofosbuvir and Velpatasvir | Velpatasvir and Sofosbuvir |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EPCLUSA 86282353 4911858 Live/Registered |
GILEAD SCIENCES IRELAND UC 2014-05-15 |